Treatment of type 1 diabetes (T1D) is entering a transformative era. The first immunotherapy approved to delay clinical onset—Teplizumab—has received FDA approval in the United S...

Many patients believe brand-name drugs are always safer than generics. But that’s a misunderstanding.Drug safety depends on regulation, not branding.What’s the Difference?An orig...

WHO Releases First GLP-1 Obesity Treatment Guideline, Signaling New Opportunities for the Global Pharma IndustryThe World Health Organization (WHO) has issued its first global guid...

 Recently, full data from the Phase II IDeate-Lung01 study on the antibody-drug conjugate I-DXd in previously treated extensive-stage small-cell lung cancer (ES-SCLC) were publish...

Pharmacil is a key pharmaceutical company under the Radiant Group in Bangladesh. Established in 2005 and headquartered in Dhaka, Bangladesh, it boasts modern pharmaceutical prod...

Obesity has become a major global public health challenge. According to the World Obesity Federation, approximately 3 billion people worldwide were overweight or obese by 2024. Exc...

Global Diabetes Situation: Over 1 in 10 Adults Affected, Prevention Is More Urgent Than EverDiabetes has long ceased being a disease confined to affluent nations—it has evolved in...

The Global Cancer Landscape: From First- to Third-Generation Targeted Drugs — How Medicine Is Changing the Fate of CancerNot long ago, a cancer diagnosis was almost a death senten...

When diagnosed with thrombocytopenia (low platelet count), many patients worry: “Does this mean I can’t live normally?” The answer is: you can, but your lifestyle will require s...

September 30, 2025 — Gilead’s Epclusa (sofosbuvir/velpatasvir, 400mg/100mg) continues to reshape hepatitis C management worldwide. As the first and only all-oral, pan-genotypi...